Notice2023-08642
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 25, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 79 (Tuesday, April 25, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 79 (Tuesday, April 25, 2023)]
[Notices]
[Pages 25003-25004]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-08642]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dr. Benjamin Hurley at
240-669-5092 or <a href="/cdn-cgi/l/email-protection#d2b0b7bcb8b3bfbbbcfcbaa7a0beb7ab92bcbbbafcb5bda4"><span class="__cf_email__" data-cfemail="e68483888c878b8f88c88e93948a839fa6888f8ec8818990">[email protected]</span></a>. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Engineered Cell-Penetrating Monoclonal Antibody for Universal Influenza
Immunotherapy
Description of Technology:
Influenza remains a burden on public health, as current treatments
of viral infections remain ineffective due to frequent virus mutations.
Many current influenza treatments rely on targeting surface viral
glycoproteins. Unfortunately, these glycoproteins are primary targets
of the immune system, which results in increased selection
[[Page 25004]]
pressure and mutational rate, leading to the well-known seasonal
variation of influenza virus. In contrast, the nucleocapsid viral
protein (NP), located in the interior of the virus, is more conserved
and an ideal antibody target; however, NP is inaccessible to
extracellular antibodies produced in response to infection. To
circumvent the challenge of targeting NP, scientists at NIAID have
developed an antibody genetically fused with a cell penetrating peptide
(CPP-mAb) that targets NP within infected cells to effectively inhibit
viral replication. By targeting NP rather than the surface
glycoproteins, this CPP-mAb can treat more influenza variants,
potentially across flu seasons, and is an improvement upon current
influenza treatments.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Clinical Treatment: CPP-mAbs against influenza NP may be a
reliable and effective method to treat patients infected with varying
subtypes of influenza, by targeting a functionally conserved protein.
<bullet> CPP-mAbs could be a viable alternative to the treatment of
influenza when other treatments are ineffective, potentially lowering
the mortality and morbidity rates in populations susceptible to
influenza infection.
Competitive Advantages:
<bullet> Current vaccines remain effective for a short time period,
due to the ever-changing nature of the viral surface glycoproteins.
CPP-mAbs could remain effective for a longer time period by targeting
the interior NP of influenza, which is more conserved across influenza
subtypes.
<bullet> Other attempts to produce vaccines against conserved
portions of the surface viral glycoproteins have failed to produce a
robust and reliable vaccine. CPP-mAbs could be a more reliable
therapeutic agent compared to alternatives, potentially effective
across flu seasons.
<bullet> In vivo efficacy: CPP-mAbs against NP increase
survivorship in mice infected with mouse Influenza A virus,
demonstrating therapeutic protection.
Development Stage:
<bullet> Pre-Clinical.
Inventors: Jonathon Yewdell, MD, Ph.D. and Ivan Kosik, Ph.D., both
from NIAID.
Publications: Publication pending.
Intellectual Property: HHS Reference No. E-193-2021; US Provisional
Application No. 63/365,841, filed on June 3rd, 2022.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-669-5092 or <a href="/cdn-cgi/l/email-protection#b7d5d2d9ddd6daded999dfc2c5dbd2cef7d9dedf99d0d8c1"><span class="__cf_email__" data-cfemail="f092959e9a919d999ede9885829c9589b09e9998de979f86">[email protected]</span></a>, and
reference E-193-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this invention. For collaboration
opportunities, please contact Benjamin Hurley; 240-669-5092,
<a href="/cdn-cgi/l/email-protection#ceacaba0a4afa3a7a0e0a6bbbca2abb78ea0a7a6e0a9a1b8"><span class="__cf_email__" data-cfemail="5436313a3e35393d3a7a3c212638312d143a3d3c7a333b22">[email protected]</span></a>.
Dated: April 19, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-08642 Filed 4-24-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 25, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.